Contact us on [email protected] to request additional information.
A segregated investment portfolio centred around creating globally competitive companies by leveraging the strengths and attributes of different geographical areas of the world to accelerate the benefit new discoveries to mankind and the cost of better proven healthcare. Future Health will invest in Healthcare, Medical Technology and Life Sciences companies, with a particular focus on ageing and related illness including brain health, general wellness, oncology and immunotherapy, cardio- vascular disease, and immunology and infectious disease.
View Teaser Below
MyDoc, South Asia’s leading telemedicine service, aims to bring primary care to patients in a region where as many as 400 million persons have no access to a doctor. It has commenced a 6 country roll-out into the Philippines, Thailand, Malaysia, Vietnam and Indonesia notably under the aegis of the insurance companies Prudential and Aetna. Wavemaker and UST Global have invested and we are seeking to close a convertible round of 2 million USD ahead of a 15-20 million USD B round in the coming months. Given the current environment, the prospects for remote medicine are more compelling than ever.View Video
Attomarker, an investee company of Milltrust’s British Innovation Fund, is an early-stage diagnostics company that has invented a new, simple to use, point-of-care blood testing device that can perform multiple tests from a single pinprick of blood in approximately five minutes. The patented Attomarker technology uses a disposable credit-card sized chip that slots into a handheld device docked to an iPhone and provides rapid testing for the healthcare professional and the consumer markets. Alongside its response to COVID-19, Attomarker is continuing its work towards developing tests for fatty liver disease (a precursor of type-2 diabetes), food allergy diagnosis and to distinguish between bacterial and viral infections. Attomarker’s COVID-19 test utilises the same technology but the application is a through a specially designed device, the Attomarker Liscar 4. Attomarker was recently selected as a candidate for the Longitude Prize, an 8 million GBP award in the fight against anti-microbial resistance. Additionally, its technology is now part of an exhibition at the Science Museum in London.
View Presentation Below
Vaccitech is an investee company of Milltrust’s British Innovation Fund through our early participation in Oxford Sciences Innovation. The company is working on a program supported by the UK Government at the University of Oxford where co-founder Professor Sarah Gilbert has advised that she could be close to delivering a vaccine of a COVID-19 specific vector, and clinical trials are underway with over 500 patients. Vaccitech has a non-exclusive license to this work, and FDA approval is being sought. A unique element of the work at Vaccitech is the T cell component to protection, which no other research group is measuring. The Vaccitech vaccine is showing significant efficacy in stimulating high levels of T cells needed to protection whereas DNA, RNA and protein-based vaccines do not. The series A post money valuation of the company was 86 million USD and the company is now seeking a minimum of 55 million USD which will fund the COVID-19 vaccine development, in addition to its other ongoing work, allowing the firm to manufacture tens of millions of doses later this year. Vaccitech has also promising clinical data from a phase 1 trial for MERS and is scheduled to commence an additional study in Saudi Arabia as soon as travel restrictions permit.
View Presentation Below
Cura Systems is a Singapore based team who have developed a CQC compliant digital health care solution for care homes. They now have 83 homes as clients in UK and 4 in Singapore and are growing fast.
View Presentation Below
The offering documents for the CerraCap II SP, a portfolio of the Milltrust International Investments SPC are only available as follows:
– To residents in Singapore, if they are a “qualified investor” as such term is defined in paragraph 5(3) of the Second Schedule to the Securities and Futures (Licensing and Conduct of Business) Regulations (Cap. 289, Rg. 10) of Singapore (SFLCBR) as may be amended or re-enacted from time to time.
– If resident in Singapore, I/We hereby certify that I/we am/are a “qualified investor” as defined above.
– To residents in Hong Kong, if they are a “professional investor”, as such term is defined in section 1 of Part 1 of Schedule 1 to the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (SFO) and any rules made under the SFO.
If resident in Hong Kong, I/We hereby certify that I/we am/are a “professional investor” as defined above.
I/We hereby indemnify and hold harmless Milltrust International Investments SPC acting on behalf of CerraCap II SP, East India Capital Management Pte. Ltd., any other member of the group of entities owned by Milltrust International Group (Singapore) Pte. Ltd. and their respective directors, members, partners, agents, officers and anyone acting on their behalf from and against all damages, losses, costs and expenses (including, without limitation, reasonable attorneys’ fees) which they may incur by reason of any material breach of the above representations and warranties made by me/us.
For professional investors only. This document is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International LLP, incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Agricultural Investments Ltd is an affiliate of Milltrust International LLP. The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International LLP or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not create a fiduciary relationship between such person and Milltrust International LLP. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this document before making any decisions based on such information or other content rests with the user and their professional advisers.